Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Results Roche YTD17 | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Results Roche YTD17

Pharmaceutical sales up 5% YTD

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche
YTD Revenues: CHF 39.4 billion (+5%)
Comments: For the first nine months, Pharmaceutical sales were CHF 30.6 billion for the first nine months, up 5% driven mainly by Ocrevus (CHF 500 million), Tecentriq (CHF 355 million) and Perjeta (CHF 1.6 billion, up 17%). Ocrevu was recently launched for relapsing and primary progressive multiple sclerosis and Tecentriq saw an uptick in metastatic bladder cancer and in metastatic non-small cell lung cancer (NSCLC).MabThera/Rituxan sales were CHF 5.6 billion, up 2%. Herceptin sales were CHF 5.2 billion, up 2%. Avastin sales were down 2% to CHF 5.0 billion. Xolair sales were up 17% to CHF 1.3 billion. Lucentis sales were CHF 1.1 billion, up 4%. Activase/TNKase sales were CHF 920 million, up 14%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters